drugset / Trial / NCT00180128
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Non-randomizedSingle-groupOpen-labelPrevention
Summary
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA is performed.
Timeline
- Start
- 2000-01
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | All-trans Retinoid acid | Unknown | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Daunorubicin | Small molecule | — | — |
| Subject | Idarubicin | Small molecule | — | — |
| Subject | Mitoxantrone | Small molecule | — | — |